Led by Molten Ventures with significant participation from ACT Venture Capital, Seroba, Charles River Laboratories, IRRUS Investments, HBAN Medtech Syndicate, and Nextsteps Capital, the funding will advance Deciphex's mission to democratise access to high-quality pathology through a technology-enabled global network of pathologists.

With over 70% of healthcare decisions requiring pathology investigation and a widening gap between rising patient needs and declining pathologist numbers, healthcare systems face mounting backlogs globally. Deciphex's products address this crisis through AI-powered digital pathology that enables pathologists to work up to 40% faster while maintaining diagnostic accuracy.

By expanding access to quality pathology services and reducing diagnostic delays, Deciphex is transforming patient care delivery worldwide.

Donal O'Shea, Founder and CEO of Deciphex, described the importance of this investment: "This investment accelerates our mission to transform global pathology access. Our ergonomic, AI-enabled platform enhances diagnostic workflow and accuracy – allowing experts to clear backlogs faster without compromising quality. By expanding this technology worldwide, we're not just improving healthcare efficiency, we're supporting both the pathologists who drive diagnoses and the patients who depend on them."

Inga Deakin, Investor at Molten Ventures, the lead investor, added: "Deciphex is tackling one of healthcare’s most pressing issues. By supporting pathologists with AI tools that enhance efficiency without sacrificing accuracy, Deciphex offers a much-needed solution to the diagnostic burden facing pathologists around the world. We’re thrilled to support Deciphex in bringing these critical diagnostic services to those who need it most."

For more startup news, check out the other articles on the website, and subscribe to the magazine for free. Listen to The Cereal Entrepreneur podcast for more interviews with entrepreneurs and big-hitters in the startup ecosystem.